Subscriber access provided by UNIV NEW ORLEANS
Review
64Cu2+ Ions as PET Probe: An Emerging Paradigm in Molecular Imaging of Cancer Rubel Chakravarty, Sudipta Chakraborty, and Ashutosh Dash Mol. Pharmaceutics, Just Accepted Manuscript • DOI: 10.1021/acs.molpharmaceut.6b00582 • Publication Date (Web): 06 Oct 2016 Downloaded from http://pubs.acs.org on October 7, 2016
Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
Molecular Pharmaceutics is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.
Page 1 of 48
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
64
Cu2+ Ions as PET Probe: An Emerging Paradigm in Molecular Imaging of Cancer Rubel Chakravarty,* Sudipta Chakraborty and Ashutosh Dash
Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400 085, India
Short title: 64Cu2+ Ions as PET Probe
*To whom all correspondences must be addressed: Rubel Chakravarty, Ph.D. E-Mail:
[email protected],
[email protected] Phone: +91-22-25590624 Fax: +91-22-25505151
1
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 2 of 48
ABSTRACT Positron emission tomography (PET) imaging has transformed diagnostic nuclear medicine and become an essential strategy in cancer management. With the expected growth of this molecular imaging modality, there is a recognized need for new PET probes to address the clinical challenges in the early diagnosis and staging of various types of cancers. In this endeavor, the prospect of using 64Cu in the form of simple Cu2+ ions as PET probe is not only a cost-effective proposition, but also seems poised to broaden the palette of molecular imaging probes in the foreseeable future. The usefulness of 64Cu2+ ions as PET probe is based on the fact that Cu is an essential element which plays an important role in cell proliferation and angiogenesis. Over the last few years, there has been continuous flow of evidences based on studies in animal models on the uptake of
64
Cu2+ ions in different types of tumors,
including, hepatoma, colorectal cancer, prostate cancer, lung cancer, breast cancer, head and neck cancer, fibrosarcoma, melanoma, glioblastoma and ovarian cancer. The widespread preclinical success of
64
Cu2+ ions as PET probe has recently resulted in translation of this
radiotracer to clinical settings for non-invasive imaging and staging of prostate cancer in human patients. In this concise review, we have focused on the latest developments in PET imaging of cancer in preclinical and clinical settings using
64
Cu2+ ion as a probe and
discussed the challenges and opportunities for future development.
Keywords: Cancer, 64Cu, Cu2+ ion, Molecular imaging, PET, Radiotracer, Theranostics
2
ACS Paragon Plus Environment
Page 3 of 48
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
INTRODUCTION Molecular imaging has become a vital tool in management of several diseases, including, cancer and is growing rapidly as one of the most exciting areas of scientific research.1-9 Not only it offers the scope for non-invasive and real time in vivo visualization of physiological processes at the cellular and molecular level in living organisms, but also provides an useful means of understanding the integrative biology of the disease process, early detection and staging of the disease, and assessment of therapeutic efficacy. Currently, various imaging modalities, such as, single photon emission computed tomography (SPECT), PET, magnetic resonance imaging (MRI), computed tomography (CT), optical imaging, ultrasound imaging, etc., are being employed to evaluate specific molecular targets in biomedical and clinical settings. 10-14 Among various molecular imaging modalities, the growth of PET imaging technology has been phenomenal over the last decade.
15-21
This is particularly because PET imaging
technology provides the scope to assess living systems by use of probes comprising of positron emitting radioisotopes with high sensitivity of measurement and accurate quantification.
17-21
This technology can aid toward improved and cost-effective decision
making and proceed only the right patients for tailored therapeutic regimens.
15
One of the
most important aspects in molecular imaging with PET is the development of appropriate PET probes,
16, 22-24
which has now engaged a growing cadre of researchers from various
scientific disciplines, including, radiochemistry, medical physics, molecular biology, engineering and medicine. The choice of the radioisotope for development of a PET probe depends on its physical and chemical characteristics, production feasibility, availability, and the timescale of the biological process which is planned to be investigated. Among various radioisotopes studied,
64
Cu (t½ = 12.7 h, E.C. 45%, β- 37.1%, β+ 17.9%) is unique as it decays by three 3
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 4 of 48
different routes, namely, electron capture (EC), β- and β+ decays (Figure 1).
25
Due to
simultaneous emission of both β+ and β- particles, this radioisotope holds promise toward development of PET imaging probes for non-invasive visualization of diseases and can also be used in targeted radiotherapy.
25
interest toward development of new efforts from the academia.
26-36
Over the last 2 decades, there has been widespread 64
Cu-based probes for PET imaging mainly due to the
Though the potential of many of these probes could be
effectively demonstrated in preclinical settings, very few of them could actually be translated to the clinics.
37-40
Diacetyl-2,3-bis(N4-methyl-3-thiosemicarbazone) (ATSM) labeled with
64
Cu (64Cu-ATSM) is one such probe that has been extensively utilized in nuclear medicine
clinics for PET imaging of hypoxia.
41-45
PET imaging using this radiotracer provides
clinically significant information which helps in predicting the response of the cancer patients to therapeutic regimens. It has been demonstrated that
64
Cu in its ionic form (as
64
Cu2+ ions) can directly be
used as a probe for PET imaging of various types of cancers. conventional radiopharmaceuticals, utilization of
64
46-48
Unlike majority of
Cu in this form would not require
complexation of the radioisotope with expensive targeting ligands (based on peptides, antibodies, etc.), thereby, rendering the process cost-effective. The absence of the radiolabeling step would provide a unique advantage as normal radiochemical processing in a hot-cell after target irradiation would be adequate to obtain the radiotracer in the desired form for use in PET imaging studies. Also, it would not be difficult to establish the protocol under current good manufacturing (cGMP) compliant settings, which is necessary for getting regulatory approval for clinical use of this radiotracer. The recent surge of interest in the use of 64Cu2+ ions as a cost-effective PET imaging probe has been the source of motivation to present a focussed review on this topic. This article will highlight the different routes for production of
64
Cu with an aim to identify a
4
ACS Paragon Plus Environment
Page 5 of 48
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
viable mode for large-scale production of this radioisotope to meet the global demand. The mechanism of
64
Cu2+ uptake in cancerous lesions will be discussed and the promising data
obtained to date in preclinical settings will be summarized with emphasis on quantitative estimation of tumor-targeted delivery, radioactivity accumulation in normal organs and toxicity issues associated with Cu2+ ions. The preliminary clinical success in utilization of 64
Cu2+ ions as PET probe will be highlighted and limitations of these studies shall be
discussed. Given the multidisciplinary nature of this field, the authors apologize for possible oversights of important contributions. The present review is by no means exhaustive, but intended to serve as a resource not only for the scientists and technologists to offer an impetus for further development but also for clinicians, to become familiar with the expectations, capabilities, constraints, and gratifications involved in the use of 64Cu2+ ions as probe for PET imaging.
PRODUCTION OF 64Cu Copper-64 is one of the few radioisotopes, production of which is possible both in a cyclotron as well as in a nuclear reactor.
25, 49
The different routes for production of 64Cu are
summarized in Table 1 and schematically represented in Figure 2. Production of this radioisotope in a nuclear reactor is feasible by two main routes: (a) thermal neutron capture 63
Cu (n, γ)
64
Cu and (b) fast neutron capture
64
Zn (n, p)
64
Cu reactions.
49-52
Though large-
scale production of 64Cu is possible by thermal neutron capture route, the major limitation of this approach is the low-specific activity of
64
Cu, making it unsuitable for preparation of
receptor specific radiopharmaceuticals. The specific activity of 64Cu can be increased by ~ 45 % by using highly (> 99 %) enriched 63Cu target for neutron activation. It is also relevant to mention here that the specific activity of neutron activated 64Cu can be substantially increased (up to 1000 times) by adopting the Szilard Chalmers process.53, 5
ACS Paragon Plus Environment
54
However, the specific
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
activity of
64
Page 6 of 48
Cu attained by adopting these approaches would still not be adequate for
preparation of conventional target specific radiopharmaceuticals. Moreover, Szilard Chalmers process suffers from several inherent limitations and cannot be used for large-scale production of 64Cu to meet the routine clinical requirements. On the other hand, high specific activity 64Cu in a ‘no carrier added’ (NCA) form can be produced by irradiation of reactor core.
50
64
Zn target with fast neutrons in the fast flux position of the
Copper-64 produced by this route can easily be utilized for radiolabeling of
receptor specific biomolecules for PET imaging of tumors. However, the fast flux position at the reactor core is generally not accessible for radioisotope production at majority of research reactors in the world.25, 49 Additionally, there are limitations on sample volume that can be irradiated which in turn put restrictions on the activity of
64
Cu that can be produced.
Therefore, this approach is not suitable for industrial-scale production of
64
Cu to meet the
regular demands of the nuclear medicine clinics. Copper-64 can also be produced in a NCA form by 64Ni (p, n) 64Cu nuclear reaction in a cyclotron. 49, 55-57 Nowadays, ‘state-of-the-art’ automated modules are available for fast and highly efficient separation of 64Cu from 64Ni and other extraneous radioisotopes adopting ion exchange chromatography. date have utilized
64
58-60
Majority of the preclinical and clinical studies reported to
Cu produced by this approach in a cyclotron.
25, 61
For developed
countries with excellent cyclotron facilities, this is probably the most practical option for production of
64
Cu for regular use in clinical context. However, this strategy may not be
viable in many developing nations with insufficient or no cyclotron facilities suitable for 64Cu production. Owing to the relatively short half-life of 64Cu, it is not logistically favourable for transportation of
64
Cu from limited number of cyclotron production facilities to distant user
sites, thereby restricting worldwide utility of this radioisotope for preclinical and clinical studies. 6
ACS Paragon Plus Environment
Page 7 of 48
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
For nations which have medium flux nuclear reactors for production of radioisotopes, the issue of unavailability of cyclotron facilities for 64Cu production might not be so severe, especially when imaging.
52
64
Cu is intended to be used in the form of Cu2+ ions as probe for PET
According to the database of the International Atomic Energy Agency (IAEA),
there are ~ 80 medium flux (1 × 1013 - 1 × 1014 n.cm-2.s-1) research reactors in the world already involved in radioisotope production.
62
Owing to their excellent geographic
distribution, many of these research reactors might be utilized for large-scale production and supply of neutron activated 64Cu to meet the regional demand of this radioisotope for use in PET imaging. Utilization of both research reactors as well as cyclotrons for production of 64
Cu would significantly increase the availability of this radioisotope throughout the world
and enhance its popularity in clinical context. After radiochemical processing of the irradiated target (irrespective of the production route),
64
Cu is generally available in the form of
64
CuCl2 (or
64
Cu2+ ions) solution which is
slightly acidic. Before administration in living subjects, it is diluted in saline or phosphate buffered saline medium to achieve pH in the range 6-7.
MECHANISM OF UPTAKE OF 64Cu2+ IONS IN CANCER CELLS Copper ions are essential for multiple biological processes and are indispensable to life.
63-66
They are required as catalytic cofactor of many enzymes or as important structural
component for proteins, and thus play significant roles in crucial biological functions such as biosynthesis of neurotransmitters, mitochondrial respiration, detoxification of free radicals, construction of connective tissues and blood vessels, enzyme activity, transport of oxygen and cell signalling.
65, 66
Even a slight disparity in the bioavailability of copper ions through
genetically inherited mutations or transformed environmental circumstances results in deficiency or toxicity, which might lead to adverse pathological effects. 7
ACS Paragon Plus Environment
65
Hence, it is
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 8 of 48
essential to maintain a tight control over the homeostasis of copper ions in the body to sustain a healthy life. According to an estimate, a healthy adult human being consumes 0.6 - 1.6 mg of copper daily through his diet. 63 The mechanism by which Cu2+ ions are taken up by human cells has not yet been fully understood. The present opinion is that the liver is the main organ which regulates the status of copper ions in the body, managing their distribution to serum and tissues.
63-67
The
clearance of excess copper ions from the biological system primarily takes place through the hepatobiliary route. In the body, Cu2+ ions are bound to plasma proteins (ceruloplasmin albumin, and transcuprein), which carry them to the cell surface where the enzymes (reductases) reduce Cu2+ ions to Cu+ ions, before their uptake into cells (Figure 2). In its reduced form, Cu+ ions are then transported across the cell membrane by the human copper transporter 1 (hCTR1), a 190-amino-acid protein of 28 kDa with 3 transmembrane domains with high affinity for copper (Figure 2). 63, 67 After entry into the cell, the copper ions are tightly bound by copper chaperones [cytochrome c oxidase copper chaperone (COX17), copper chaperone for SOD1 (CCS), and antioxidant protein (ATOX1)], thus keeping them in bound Cu+ state by preventing redox cycling.
63, 67
These copper chaperones deliver Cu+ ions to cytosolic SOD1, cytochrome c
oxidase (COX) in the mitochondria and to copper transporting ATPase A/B (ATP7A/B) at the trans-Golgi network (TGN), respectively (Figure 2).
63, 67
Interestingly, glutathione
(GSH) - a small cysteine containing tripeptide present inside the cell plays a safeguarding role by binding excess Cu+ ions to prevent oxidative damage due to redox cycling and thus protect the cell from copper toxicity.
63, 67
Analogous defensive mechanisms are carried out
by metallothioneins (MTs), a family of cysteine rich small proteins, capable of irreversibly binding Cu+ ions. 63, 67 When intracellular copper is elevated beyond a certain level, hCTR1 is internalized and is then destroyed. During this process, copper transporting ATPase A/B 8
ACS Paragon Plus Environment
Page 9 of 48
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
(ATP7A and ATP7B) transfer from the TGN to the plasma membrane to help in excretion of copper from the cell. Since copper plays an important role in many cellular functions, it is involved not only in cancer development but can also aid toward cancer growth, angiogenesis and metastasis.
63, 67, 68
Several researchers have reported in the past that an elevated level of
copper accumulation is observed in malignant tissues.
63, 67
This is particularly because
hCTR1 is generally overexpressed in several cancer cells, which include, prostate cancer, lung cancer, glioblastomas, liver cancer, breast cancer, and melanoma.
46, 48, 63, 67
Based on
this knowledge, it was proposed that hCTR1 could be used as a promising target for molecular imaging of a wide variety of cancers. 63, 67, 68 Increased copper uptake in the cancer cells could easily be tracked in vivo using radioactive copper (64Cu2+) ion as a radiotracer. This forms the basis of the proposition that 64Cu2+ ion can serve as an effective biomarker for non-invasive assessment of cancer using PET imaging technology. Although increased 64Cu2+ ion uptake in cancerous lesions could be described on the basis of overexpression of hCTR1, it is pertinent to point out here that no attempt has yet been made to understand the exact chemical form of the administered copper ions in blood serum. The in vivo behavior of Cu2+ metal ions can be theoretically understood by speciation modelling of blood serum,
69
and can be experimentally corroborated by various analytical
techniques. 70 Such studies would aid toward exact determination of copper species formed in blood serum after in vivo administration of Cu2+ ions, investigation of the processes leading to their formation or conversion and assessment of these processes in terms of kinetic and equilibrium parameters. The viable modes for large-scale production of 64Cu and its utilization in the form of Cu2+ ion for tumor targeting are schematically illustrated in Figure 2.
9
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 10 of 48
PRECLINICAL STUDIES USING 64Cu2+ IONS AS PET PROBE Over the last 10 years, there have been numerous reports on utilization of 64Cu2+ ions as probe for PET imaging in mouse models of cancers, including, hepatoma, colorectal cancer, prostate cancer, fibrosarcoma, melanoma, ovarian cancer, glioblastoma, head and neck cancer, lung cancer and breast cancer. 46-48 The high-affinity mouse copper transporter 1 (mCTR1) plays the same role as hCTR1 and is responsible for increased cellular copper uptake in murine cancers.
46-48
Most of these reported studies were based on the use of
cyclotron produced NCA 64Cu. It was only recently that the utility of neutron activated 64Cu produced in a research reactor could be demonstrated for cancer targeting.
52
These
preclinical studies exploring the utility of (a) cyclotron produced and (b) reactor produced 64
Cu in the form of Cu2+ ions for non-invasive assessment of cancers are summarized in
Table 2 and elaborated in the following text. Cyclotron Produced 64Cu2+ Ions as PET Probe for Cancer Imaging The utility of cyclotron produced NCA 64Cu2+ ion as a probe for cancer imaging was first reported more than 10 years back by Peng et al.
71
In this study, the authors utilized
64
Cu2+ ions as probe for PET imaging of hepatoma xenografts in mouse model. In vivo PET
imaging studies after intravenous administration of the radiotracer showed significantly higher tumor uptake in comparison to the uptake in the muscles at 1 h post-injection (p.i.). However, the PET images also showed high radioactivity uptake in the liver, probably due to significant level of mCTR1 expression in this organ. Though this preliminary study revealed that this radiotracer was not suitable for detection of primary hepatic cancer, it might be a practical choice for revealing extrahepatic metastasis of the primary cancer in the organs or tissues (such as bones, muscles and brain), which otherwise show much lower uptake of 64
Cu2+ ions.
10
ACS Paragon Plus Environment
Page 11 of 48
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
The same group of authors also utilized prostate cancer xenograft model in mice.
47
64
Cu2+ ions as PET probe for imaging of
In vivo PET imaging and biodistribution studies
showed significant accumulation of radioactivity (4.4 ± 1.1 %ID/g) in the tumor at 24 h p.i., with good target-to-background contrast (Figure 3A). As expected, a high uptake (17.5 ± 3.9 %ID/g) of radioactivity in the liver was observed due to elevated level of mCTR1 expression in this organ. Due to high liver uptake, this radiotracer might not be a suitable choice for detection of hepatic metastases of prostate cancer. Also, it was found that this radiotracer cleared from the system mainly through hepatobiliary route, which might lead to issues related to visualization of abdominal metastases. To corroborate the findings of PET imaging studies, the authors carried out immunohistochemistry study with hCTR1-specific antibody and showed significant level of hCTR1 immunoreactivity in the tumor tissue (Figure 3B). This study was further pursued by the same group of authors to investigate whether enhanced uptake of
64
Cu2+ ions in prostate cancer was indeed due to hCTR1 mediated pathway, or
simply because of non-specific binding of
64
Cu2+ ions to tumor tissue.
72
The authors also
evaluated the function of hCTR1 in proliferation and growth of prostate cancer. For this purpose, a lentiviral vector encoding short-hairpin ribonucleic acid (RNA) specific for hCTR1 (lenti-hCTR1-RNA) was made for RNA interference-mediated knockdown of hCTR1 expression in prostate cancer cells. The authors determined the extent of hCTR1 knockdown by Western blot analysis, and examined the outcome of hCTR1 knockdown by in vitro evaluation of 64Cu-uptake in prostate cancer cells and cell proliferation assay. The results of these studies suggested that RNA interference-mediated knockdown of hCTR1 was responsible for decreased uptake of 64Cu in prostate cancer cells and the inhibition of cancer cell proliferation. Further, the consequence of hCTR1 knockdown on the uptake of
64
Cu2+
ions in the tumor was established by in vivo PET imaging and biodistribution studies in mice bearing prostate cancer xenograft (DU-145 and PC-3 tumors). These studies revealed that the 11
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
uptake 64Cu2+ ions in the tumors with knockdown of hCTR1 (4.02 ± 0.31 %ID/g in PC-3 and 2.30 ± 0.59 %ID/g in DU-145) was considerably lesser than the radioactivity uptake in the control tumors without knockdown of hCTR1 (7.21 ± 1.48 %ID/g in PC-3 and 5.57 ± 1.20 % ID/g in DU-145) at 24 h p.i. (Figure 3C). Additionally, the volumes of tumors with knockdown of hCTR1 (179 ± 111 mm3 for PC-3 or 39 ± 22 mm3 for DU-145) were much lesser than those without knockdown of hCTR1 (536 ± 191 mm3 for PC-3 or 208 ± 104 mm3 for DU-145). Though the authors could not explain the exact mechanism of inhibition in tumor growth by hCTR1 knockdown, the promising results obtained in this study amply demonstrated that hCTR1 is a promising target for PET imaging of prostate cancer using 64
Cu2+ ions as probe. The utility of
64
Cu2+ ions as a PET radiotracer for non-invasive imaging of hCTR1
overexpression in breast cancer xenograft model was reported by Kim et al. 46 In this study, a lentiviral vector intrinsically expressing the hCTR1 gene was used to infect human breast cancer cells (MDA-MB-231) and positive clones (MDA-MB-231-hCTR1) were chosen for the study. The expression of hCTR1 gene in MDA-MB-231-hCTR1 cells was confirmed by reverse transcription polymerase chain reaction, Western blot assay, and cellular 64Cu uptake level. The radiotracer was intravenously administered in mice bearing MDA-MB-231 and MDA-MB-231-hCTR1 tumor xenografts. In vivo PET imaging studies showed an increased uptake of 64Cu in MDA-MB-231-hCTR1 tumors (5.373 ± 1.098 %ID/g) than in MDA-MB231 tumors (2.581 ± 0.254 %ID/g) at 48 h p.i. of the radiotracer (Figure 4A). These results were further corroborated by immunohistochemistry study which showed that there was negligible hCTR1 immunoreactivity signal in the MDA-MB-231 tumor tissue, while there was a mixed type of hCTR1 expression in the MDA-MB-231-hCTR1 tumor tissue as indicated by intense spots on some of the cells (Figure 4B). The results of this study further established the potential utility of hCTR1 gene for cancer diagnosis using PET. 12
ACS Paragon Plus Environment
Page 12 of 48
Page 13 of 48
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
In another interesting study, Jorgensen et al determined the degree of
64
Cu2+ ion
accumulation in xenograft models of different types of human cancers, such as, U87MG (glioblastoma), HT29 (colorectal cancer), H727 (neuroendocrine lung cancer), FaDu (head & neck cancer), and A2780 (ovarian cancer).
73
In vivo PET imaging studies showed almost
comparable uptake of the radiotracer in U87MG (3.48 ± 0.35 %ID/g), H727 (3.13 ± 0.12 %ID/g) and FaDu (3.04 ± 0.18 %ID/g) tumors at 1 h p.i., while the uptake in HT29 (2.20 ± 0.18 %ID/g) and A2780 (1.53 ± 0.07 %ID/g) tumors were significantly lower at the same time-point (Figure 5). The authors also compared 64Cu2+ ion accumulation in tumor tissue to hCTR1 expression in the different types of tumors by quantitative real-time polymerase chain reaction measurement. Despite differences in 64Cu2+ ion uptake in the tumor models studied, no definite relationship between the gene expression of hCTR1 and 64Cu2+ ion accumulation could be found. The potential of
64
Cu2+ ions as a radiotracer for both PET imaging and targeted
radiotherapy of malignant melanoma was evaluated for the first time in preclinical settings by Qin et al.
48
In this study, the authors selected two melanoma cell lines (melanotic B16F10
and amelanotic A375M) and confirmed the high level of hCTR1 expression by Western blot analysis. As expected, 64Cu2+ ions showed significantly elevated and specific uptake in both B16F10 as well as A375M cells. The radiotracer was administered in mice bearing melanoma tumors (B16F10 and A375M) and subjected to in vivo PET imaging after different time intervals p.i. (Figure 6A). The PET imaging studies revealed significant radioactivity uptake (~ 4 %ID/g at 4 h p.i.) in both B16F10 and A375M tumors, with good target-to-background ratio. The radioactivity accumulation in the tumor then remained at comparable levels until 72 h p.i. (3.48 ± 0.34 %ID/g), while uptake in the non-targeted organs decreased significantly. On the basis of the promising results obtained from the PET imaging studies, the authors further studied the therapeutic efficacy of 64Cu2+ ions in melanoma (B16F10 and 13
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 14 of 48
A375M) tumor bearing mice. For this purpose, mice bearing melanoma tumors were intravenously administered with
64
Cu2+ ions (~ 74 MBq) or phosphate-buffered saline (as
control) and the tumor sizes were examined over the period of therapy. This study showed that the growth of both B16F10 and A375M tumors under
64
Cu2+ ions therapy was much
slower than what was observed in the control group (Figure 6B), thus, establishing the efficacy of this radiotracer for cancer theranostics. In a similar study, Ferrari et al studied the theranostic potential of 64Cu2+ ions in mice bearing glioblastoma tumor (U87MG) xenograft.
74
In vivo PET imaging and biodistribution
studies demonstrated significant tumor uptake [maximum standardized uptake value (SUVmax) = 3.6 ± 0.44] with good target-to-background ratio. In therapy studies, the authors divided the tumor bearing mice into 3 groups as follows: (a) mice not administered with 64
Cu2+ ions (non-treated or control group), (b) mice treated with a single administration of
333 MBq of
64
Cu2+ ions (single-dose group), and (c) mice treated with a multiple-doses of
64
Cu2+ ions (multiple-dose group), each of 55.5 MBq administered daily over 6 days. The
theranostic potential of the radiotracer was examined by performing PET imaging at 1 week and 20 weeks after completion of therapy. From the PET images, the reduction in tumor volume was estimated semi-quantitatively by a direct calculation of the volume of interest (VOI). The authors observed a significant reduction in tumor volume (ranging from 70 - 90 %) over the control group in both single-dose group as well as multiple-dose group. Also, a significant increase in survival rates in mice treated with
64
Cu (both single-dose group and
multiple-dose group) was observed in comparison to the survival rate in the control-group ( < 0.005). However, not much difference in therapeutic efficacy was observed between the results of single- and multiple-dose administration and the relative advantages or disadvantages of one therapeutic protocol over the other could not be established.
14
ACS Paragon Plus Environment
Page 15 of 48
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
Reactor Produced 64Cu2+ Ions as PET Probe for Cancer Imaging Recently, Chakravarty et al. demonstrated the utility of 64Cu (in the form of Cu2+ ions) produced by neutron activation route in a medium flux research reactor for cancer imaging. 52 Since the specific activity of
64
Cu produced by this route is low (~ 3 TBq/g), it was
anticipated that administration of relatively large quantities of Cu2+ ions in the biological system might lead to aggregation of serum proteins incorporating such aggregates after in vivo administration of
64
Cu.75-77 Formation of
64
Cu2+ ions would lead to high radioactivity
uptake in the reticuloendothelial system (RES). Under such situation,
64
Cu-incorporated
protein aggregates would be excreted mainly through the hepatobiliary route and negligible radioactivity accumulation in the tumor would be observed. This issue of aggregation of proteins present in blood serum 75-77 was not a matter of serious concern in earlier preclinical studies which used cyclotron produced NCA
64
Cu. This is because of the extremely low
concentration of Cu2+ ions in NCA 64Cu, which are not expected to play any significant role in protein aggregation. In order to further understand the phenomenon of serum protein aggregation in presence of Cu2+ ions, dynamic light scattering (DLS) studies were performed after addition of different concentrations of Cu2+ ions in mouse serum. 67,78 The DLS studies demonstrated that aggregate formation would occur at a concentration > 20 µg Cu / mL of serum. This observation was further confirmed by examination of the dispersion behavior (adopting magnetic T2 relaxation time measurement and radio-thin layer chromatography assay) of the mouse serum medium containing Cu2+ ions (Figure 7). From these studies, it could be inferred that 64Cu2+ ions at a concentration ≤ 20 µg Cu / mL would not lead to aggregation of serum proteins. Based on these results, the authors argued that the radioactivity corresponding to this threshold concentration of Cu2+ ions was adequate for PET imaging with decent contrast in both preclinical and clinical settings and there should not be any 15
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
technical issue toward utilization of low specific activity
Page 16 of 48
64
Cu2+ ions as probe for cancer
imaging. In order to demonstrate the tumor targeting efficacy of low specific activity
64
Cu2+
ions, the radiotracer was intravenously administered in melanoma tumor bearing mice and fibrosarcoma tumor bearing mice.
52
The biodistribution studies showed significant
accumulation of radioactivity in the tumor (7.64 ± 1.61 %ID/g in melanoma, 6.54 ± 1.41 %ID/g in fibrosarcoma) within 4 h p.i., with good target-to-background ratio (Figure 8). It is interesting to note that the biodistribution pattern observed after administration of low specific activity
64
Cu2+ ions was comparable to that observed with NCA
64
Cu2+ ions. This
could probably be attributed to the transporter protein (hCTR1) based uptake mechanism of Cu2+ ions, as discussed earlier. However, it is essential to assess the role of specific activity of 64Cu2+ ions on tumor uptake as such a study might establish whether cold Cu2+ ions present in the radioactive solution have any saturation effect with regards to tumor uptake or exhibit toxicological issues. Such a study might also aid in determining the threshold specific activity limit of reactor produced 64Cu in order to use this radioisotope in the form of its divalent ions as PET probe for cancer imaging. Nevertheless, the encouraging results obtained in this preliminary study might enable extensive use of low specific activity 64Cu for non-invasive imaging of cancer.
CLINICAL STUDIES USING 64Cu2+ IONS AS PET PROBE The utilization of 64Cu2+ ions as an effective probe for PET imaging of human cancer has begun to be explored in the nuclear medicine clinics only recently. Presently, there are very few published reports on clinical deployment of 64Cu2+ ions directly as a radiotracer for cancer imaging and all the clinical studies reported to date have used NCA 64Cu produced in a cyclotron.
79
The first clinical study on utilization of
64
Cu2+ ions as a PET probe was
16
ACS Paragon Plus Environment
Page 17 of 48
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
reported by Capasso et al., imaging using
64
80
wherein the authors have studied the applicability of PET-CT
Cu2+ ions as probe in staging of prostate cancer patients. In this
investigational clinical trial, seven prostate cancer patients (confirmed by histological studies performed earlier) were enrolled. These patients also undertook MRI to confirm the disease. Among these patients, three went through adrenal deprivation therapy (ADT) at time of PET imaging, while the other four patients did not undergo any therapeutic procedure. In all these patients, ~ 339 MBq of 64Cu2+ ions were intravenously administered and PET-CT scans were performed. The PET-CT scans showed that the radiotracer cleared mainly through the hepatobiliary route and excretion through the renal route was bare minimum. This is in fact an undesirable phenomenon because possible cancerous lesions in the pelvic area and abdomen cannot easily be identified by PET imaging. Primary prostate cancer lesions could be detected within 1 h p.i., with appreciably good tumor-to-background ratio. The radiotracer uptake was higher (SUVmax = ~ 7 at 1 h p.i.) in primary tumors of patients without ADT than in patients who had undergone this therapy (SUVmax = ~ 4 at 1 h p.i.). No undesirable or clinically measurable pharmacologic effect was observed in any of these patients. The major limitation of this study was that a small number of patients were enrolled and the PET imaging data were not validated by histological evaluation. However, this preliminary study demonstrated the potential of PET-CT imaging using 64Cu2+ ions as probe for initial staging of prostate cancer patients. Recently, Panichelli et al demonstrated the utility of 64Cu2+ ions for PET imaging of brain tumors in patients affected by glioblastoma.
81
In this study, 19 patients with a known
history and radiological confirmation of cerebral tumors were registered. After initial cerebral MRI, patients were administered with
64
Cu2+ ions (13 MBq/kg). PET-CT imaging of brain
clearly showed the cancerous lesions at 1 h p.i., with steady retention of radioactivity up to 24 h. Good concurrence was found between the results obtained from PET-CT imaging and 17
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
MRI. As expected, the radioactivity cleared quickly from the blood and was mainly excreted through hepatobiliary route. The results of this preliminary clinical study showed the potential of
64
Cu2+ as a diagnostic tracer for glioblastoma multiforme. Interestingly, in a
recent review, PET-CT images from patients with prostate and brain tumors administered with
64
Cu2+ ions were reported.
79
Although, the details of these studies and the clinical
implications of these results were not provided, the PET images reported are certainly outstanding and holds tremendous promise, mainly because they demonstrate the efficacy of simple
64
Cu2+ ions as an effective radiotracer for PET imaging of cancers with excellent
contrast (Figure 9).
TOXICOLOGICAL CONCERNS ON IN VIVO ADMINISTRATION OF 64Cu2+ IONS FOR PET IMAGING An obvious concern while using
64
Cu2+ ions as probe in PET imaging of cancer in
human subjects might be the cytotoxicity of copper.
82-86
Even though copper is a necessary
element that is vitally important for human health, overexposure of copper ions can produce a wide spectrum of side effects.
85, 86
This is particularly because excess copper ions can
contribute toward Fenton-type reaction, resulting in formation of radical species that can cause oxidative stress and consequent damage to lipids, proteins, and nucleic acids in the living system. 85-88 It has been reported that the cytotoxic effects of copper ions are apparent only at concentration ≥ 7.42 mg/L.
85, 86
Considering this as the threshold limit, cytotoxicity effects
are not a matter of serious concern while using 64Cu2+ ions for PET imaging of cancer. 52 For PET imaging in human patients with reasonably good tumor-to-background ratio, only 185 370 MBq (5 - 10 mCi) of 64Cu2+ ions is expected to be administered. 40, 80 This clinical dose required essentially translates into few ng of Cu2+ ions when cyclotron produced NCA 64Cu is 18
ACS Paragon Plus Environment
Page 18 of 48
Page 19 of 48
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
used while it is < 0.5 mg of Cu2+ ions when low specific activity 64Cu produced in a research reactor is used for PET imaging.
52
Hence, after intravenous administration of the dose of
Cu2+ ions required for PET imaging, their overall concentration in human blood would be significantly below the cytotoxic limit since the average volume of blood in a human adult is in the range of 4-5 L.
52
Thus, it could be argued that the level of Cu2+ ions in clinically
relevant doses of the radiotracer when administered in vivo would not manifest cytotoxicity 52, 89
effects.
Safe usage of 64Cu2+ ions for cancer imaging using PET was also proven by the
earlier utilization of this radiotracer for evaluation of copper metabolism in healthy human beings and in patients with copper metabolism problems without observing significant side 90-92
effects.
Systemic toxicity or clinically detectable pharmacologic effects were also not
observed in prostate cancer patients who were administered with 64Cu2+ ions,
80
thus, further
alleviating toxicity concerns regarding use of this radiotracer for clinical PET imaging.
SUMMARY AND FUTURE DIRECTIONS A review of the PET imaging of cancer using 64Cu2+ ions as probe indicates that the field is still in its infancy but is rapidly evolving. This non-invasive molecular imaging approach not only holds significant promise in the detection of primary cancer and its metastases, but can also aid toward accurate staging of cancer and examining the efficacy of the treatment. With further maturity in understanding of the molecular mechanisms of cancer and biochemical phenomenon of copper ion uptake, this approach is supposed to play a progressively important role in cancer management. Recently, the concept of PET imaging using
64
Cu2+ ions as probe has been translated to clinical settings and successfully used for
primary staging of prostate cancer patients. This recent clinical success indicated that more clinically translatable advances can be expected in near future which would lead to a positive impact on care of millions of cancer patients worldwide. 19
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 20 of 48
Despite immense potential of 64Cu2+ ions, the cost of a given probe and the logistics associated with a particular radionuclide production route needs to be considered suitably. Though the cyclotron route remains the most viable approach for production of NCA 64Cu for clinical use, simultaneous utilization of several medium flux research reactors located in different parts of the world for production of this radioisotope would enhance the global availability of this radioisotope. The low specific activity of neutron activated 64Cu is not a matter of concern when directly used as a radiotracer in the form of Cu2+ ions for PET imaging. Probably, this is the only approach by which reactor produced low specific activity 64
Cu can be effectively utilized in clinical context. With the availability of neutron activated
64
Cu, clinical use of this PET probe would intensify in future. Direct utilization of
64
Cu2+ ions as a PET probe would offer numerous advantages
over conventional PET-radiopharmaceuticals which involve radiolabeling of complex biomolecules and is poised to lower the cost of molecular imaging of cancer. The unique phenomenon of nuclear decay by emission of both β+ as well as β- particles makes
64
Cu an
ideal candidate for theranostic approaches to cancer management. Though the potential of 64
Cu2+ ions for cancer theranostics have been successfully demonstrated in preclinical
settings, detailed radiation dosimetry and toxicity assessments would be required before administering therapeutically relevant doses of this radiotracer in human subjects. Over the last few years, there is an increasing trend toward implementation of cGMP regulations for PET radiotracer preparations. With a view to achieve such a goal, a systematically planned and appropriately executed quality assurance system is of paramount importance. Also, to be successful in addressing the regulatory issues,
64
Cu production
technologies must be tailored to local legislative, regulatory and institutional conditions. In this premise, utilization of automated radiochemical processing modules will represent an
20
ACS Paragon Plus Environment
Page 21 of 48
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
intuitive vision as automation technology not only guarantees reproducible yield and purity but also complies with regulatory protocols. While most of the studies involving use of
64
Cu2+ ions directly as a radiotracer for
PET imaging remain at a proof-of-concept phase, the potential of this strategy for personalized cancer management in humans is exceedingly attractive. The progress toward the widespread clinical adaptation of this innovative approach is slow as of now but can definitely be expedited by addressing the interdisciplinary challenges and overcoming the biological barriers with concerted efforts of radiochemists, biologists, medical physicists, molecular imaging scientists, clinicians, and the regulatory authorities.
21
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 22 of 48
Table 1: Comparative assessment of different routes for production of 64Cu
Production
Target
mode
Nuclear
Cross
Neutron
Specific
Possible
Viability
Refere
reaction
section
flux/
activity
radio-
for large
nces
(b)
beam
(TBq/g
nuclidic
scale
current
of Cu)
impuriti
producti
es
on
(Reactor/ cyclotron)
Reactor
63
Cu
63
13
Cu (n,
Thermal
10 -
γ) 64Cu
4.5 ± 0.1
1014
2–6
65
Yes
52
67
Cu
No
54
Co,
Yes
56, 57
Zn,
65
Ni
Epitherm n.cm-2.s-1 al 6.1 ± 0.3 64
Zn
64
Zn (n,
p) 64Cu
0.031 ±
1013 -
~ 3.7 ×
0.002
1014
103
n.cm-2.s-1 Cyclotron
64
Ni
64
Ni (p,
n) 64Cu
0.035 ±
15 – 60
3.1 × 103
55
0.003
µA
– 1.1 ×
60
105
61
22
ACS Paragon Plus Environment
Cu, Cu
Page 23 of 48
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
Table 2: Overview of 64Cu2+ ions as probe in preclinical PET imaging of cancers
64
Cu
Cancer type
Cancer cell
Maximum
Blood
Tumor-
line used
tumor
uptake
to-
production route
uptake
References
muscle ratio
64
Ni (p, n) 64
Cu
Hepatocellular
Murine
3.7 ± 0.4
carcinoma
hepatoma
SUVmax
reaction in
cells (Hep 1-
cyclotron
6) Prostate cancer
#
~3
71
~6
47
~ 14
72
#
46
~4
73
Human
4.4 ± 1.1
0.8 ±
prostate
%ID/g
0.2
cancer cells
%ID/g
(PC-3) Human
5.6 ± 1.2
1.5 ±
prostate
%ID/g
0.5
cancer cells
%ID/g
(DU-145) Breast cancer
Human breast cancer
5.4 ± 1.1
~ 1.5
%ID/g
%ID/g
#
cells (MDAMB-231) infected with a
lentiviral
vector intrinsically expressing the
hCTR1
gene Colorectal
Human
3.0 ± 0.2
cancer
colorectal
%ID/g
cancer cells 23
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 24 of 48
(HT29) Glioblastoma
Human
3.8 ± 0.4
glioblastoma
%ID/g
cells
3.6 ± 0.4
(U87MG)
SUVmax
Head and neck
Human
4.9 ± 0.3
cancer
squamous
%ID/g
#
~4
73,74
#
~6
73
#
~6
73
#
~ 1.5
73
4.1 ± 0.1
48
3.5 ± 1.2
48
52
cell carcinoma cells (FaDu) Lung cancer
Human lung
4.9 ± 0.2
carcinoma
%ID/g
cells (H727) Ovarian cancer
Human
1.3 ± 0.1
ovarian
%ID/g
carcinoma cells (A2780) Melanoma
Murine
4.1 ± 0.2
1.5 ±
melanoma
%ID/g
0.2
cells
%ID/g
(B16F10) Human
3.6 ± 0.4
1.9 ±
malignant
%ID/g
0.6
melanoma
%ID/g
cells (A375M) 63
Cu (n, γ) 64
Cu
reaction in a
Fibrosarcoma
Murine
6.5 ± 1.4
1.0 ±
19.6 ±
fibrosarcom
%ID/g
0.4
3.1
a cells
%ID/g
(MC57G) 24
ACS Paragon Plus Environment
Page 25 of 48
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
nuclear reactor
Melanoma
Murine
7.6 ± 1.6
1.1 ±
22.5 ±
melanoma
%ID/g
0.6
3.8
cells
%ID/g
(B16F10) #
Not reported
25
ACS Paragon Plus Environment
52
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 26 of 48
Figure captions: Figure 1: Nuclear decay scheme of
64
Cu. The radioisotope decays to either
64
Ni by β+
emission or EC or to 64Zn by β- decay.
Figure 2: A schematic representation of production of 64Cu in a nuclear reactor or cyclotron, followed by radiochemical processing of the irradiated target in a hot cell facility. After radiochemical processing, 64Cu exists mainly as Cu2+ ion and is administered in vivo as a PET imaging probe. In the extracellular space, Cu2+ is reduced by reductases on the cell surface to Cu+, which is then transported across the cell membrane by the hCTR1. Adapted from reference 67 with permission.
Figure 3: (A) PET image at 24 h p.i. of 64Cu2+ ions in mouse bearing prostate cancer (PC-3) xenograft.
(B)
Immunohistochemistry
study
shows
significantly
high
hCTR1
immunoreactivity on prostate cancer xenograft tissues after incubation with an antibody specific for hCTR1. (C) PET-CT imaging at 24 h p.i. of 64Cu2+ ions to show the outcome of knockdown of hCTR1 on tumor uptake of 64Cu2+ ions in mice bearing prostate cancer (PC-3 and DU-145) xenografts. (i) Reduced 64Cu uptake in PC-3 tumor with knockdown of hCTR1 (tumor on right marked by *), compared with PC-3 tumors without knockdown of hCTR1 (tumor on left marked by **). (ii) Reduced 64Cu uptake in DU-145 tumor with knockdown of hCTR1 (tumor on right marked by *), compared with DU-145 tumor with no knockdown of hCTR1 (tumor on left marked by **). Adapted from reference 47, 72 with permission.
Figure 4: (A) PET images at different time points p.i. of 64Cu2+ ions in mouse bearing MDAMB-231 (arrow) and MDA-MB-231-hCTR1 (arrowhead) tumors. (B) Immunohistochemistry
26
ACS Paragon Plus Environment
Page 27 of 48
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
of slices from MDA-MB-231 (left) and MDA-MB-231-hCTR1 (right) tumor tissues. Adapted from reference 46 with permission.
Figure 5: Transaxial PET images of different tumor types [U87MG (glioblastoma), HT29 (colorectal cancer), H727 (neuroendocrine lung cancer), A2780 (ovarian cancer), and FaDu (head & neck cancer)] in mice at 1 h and 22 h p.i. of
64
Cu2+ ions. Tumors are indicated by
arrows. Adapted from reference 73 with permission.
Figure 6: (A) PET images at various time points p.i. of
64
Cu2+ ions in mouse bearing
melanoma (B16F10 and A375M) tumors. (B) Representative images of A375M tumor necrosis with and without treatment with
64
Cu2+ ions (left: control mouse; right: treated
mouse). Adapted from reference 48 with permission.
Figure 7: Evaluation of serum protein aggregation in presence of Cu2+ ions. (A) DLS study after addition of increasing quantities of CuCl2 in mouse serum. Particle size information was acquired by investigating the electric field correlation function, [g(τ)], where τ is the correlation time. A significant shift in g(τ) was observed only when the concentration of Cu2+ ions in mouse serum was > 20 µg / mL, representing colloidal aggregate formation. (B) Study of the dispersion behavior of Cu2+ ions in mouse serum by studying the relaxation time over 24 h time period. (C) Percentage of free 64Cu2+ ions in mouse serum over 24 h time period, as determined by radio-TLC study. Inset shows the TLC pattern of 64Cu2+ ions in mouse serum when TLC was developed in sodium citrate solution. Adapted from reference permission.
27
ACS Paragon Plus Environment
52
with
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 28 of 48
Figure 8: Biodistribution of 64Cu2+ ions when intravenously administered in mice bearing (A) melanoma tumors and (B) fibrosarcoma tumors. Adapted from reference 52 with permission.
Figure 9: Representative PET-CT images acquired after intravenous administration of 64Cu2+ ions in patients with (A) prostate cancer, (B) cerebral tumor and (C) glioma. Selective uptake of
64
Cu2+ ions can be seen in all cancerous lesions. Adapted from reference
permission.
28
ACS Paragon Plus Environment
79
with
Page 29 of 48
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
Figures 1
29
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 30 of 48
Figure 2
Reactor Production 64Zn
65
48.63 % σ = 0.76 b
Zn 244 d (n,p)
β(n,γγ ) 64Cu 69.17 % 12.9 h σ = 4.5 b 62
Ni 3.63 % σ = 14.5 b
Zn 27.9 % 65
63 Cu
β+ 63Ni
100 y
Cu 30.83 % σ = 2.17 b
Cyclotron Production
Hot Cell
66
64
Zn 48.63 % σ = 0.76 b
Irradiated target
Irradiated target
65 Zn 244 d
β-
63Cu
69.17 % σ = 4.5 b
64
Ni 0.926 % σ = 1.52 b
62
Ni 3.63 % σ = 14.5 b
Radiochemical processing 64 Cu (as Cu2+ ions)
Reductase
Cu2+
Cu+
hCTR1
hCTR1
hCTR1
30
ACS Paragon Plus Environment
66 Zn 27.9 %
64
Cu 12.9 h β+ 63
Ni 100 y
65 Cu 30.83 % σ = 2.17 b
64 Ni 0.926 % σ = 1.52 b
Page 31 of 48
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
Figure 3
A
B
5 %ID/g
0 %ID/g
C (i))
(ii))
PC-3
DU-145 8 %ID/g
0 %ID/g
31
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 32 of 48
Figure 4
A 2h
4h
12 h
24 h
15 %ID/g
0 %ID/g
B
MDA-MB-231
MDA-MB-231-hCTR1
32
ACS Paragon Plus Environment
Page 33 of 48
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
Figure 5
U87MG
HT29
H727
A2780
FaDu
%ID/g 15
1h
22 h
1
33
ACS Paragon Plus Environment
Molecular Pharmaceutics
Figure 6 A
4h
24 h
B
B16F10
2h
Control mouse
A375M
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 34 of 48
34
ACS Paragon Plus Environment
Treated mouse
Page 35 of 48
Figure 7 A
B 2500
0.9
Relaxation time (T2)
2000
0.6
1500
Blank serum 6.7 µg Cu/mL 10.0 µg Cu/mL 13.3 µg Cu/mL 20.0 µg Cu/mL 26.7 µg Cu/mL 33.3 µg Cu/mL
0.3
1000
500
0.0
0
100
1000
0
20000
40000
C 100
90 80
Radioactivity (%)
2+ Cu (%)
80
60
40
20
70 60 50 40 30 20 10 0 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
Rf
0 0
2
60000
Time (s)
Correlation time (t)
64
10
Unbound
Normalized correlation function [g(τ )]
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
4
6
8
10 12 14 16 18 20 22 24
Incubation time (h)
35
ACS Paragon Plus Environment
80000
100000
Molecular Pharmaceutics
Figure 8 A
B 60
60
Melanoma
Fibrosarcoma
1h 4h 24 h 48 h
50
1h 4h 24 h 48 h
50
40
%ID/g
40
30
30
20
20
10
10
0
0
Bl oo d Li ve r G Ki IT St dne om y ac H h ea Lu rt ng s Ti M bi us a cl Sp es le Tu en m or
Bl oo d Li ve r G Ki IT St dne om y ac He h a Lu rt ng s T M ibi us a c Sp les le Tu en m or
%ID/g
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 36 of 48
A
A
36
ACS Paragon Plus Environment
Page 37 of 48
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
Figure 9
A
B
C
37
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 38 of 48
References 1.
Herschman, H. R. Molecular imaging: looking at problems, seeing solutions. Science
2003, 302, 605-8. 2.
Chakravarty, R.; Chakraborty, S.; Dash, A. Molecular Imaging of Breast Cancer:
Role of RGD Peptides. Mini Rev Med Chem 2015, 15, 1073-94. 3.
Chakravarty, R.; Goel, S.; Cai, W. Nanobody: the "magic bullet" for molecular
imaging? Theranostics 2014, 4, 386-98. 4.
Chakravarty, R.; Hong, H.; Cai, W. Positron emission tomography image-guided
drug delivery: current status and future perspectives. Mol Pharm 2014, 11, 3777-97. 5.
Chakravarty, R.; Hong, H.; Cai, W. Image-Guided Drug Delivery with Single-Photon
Emission Computed Tomography: A Review of Literature. Curr Drug Targets 2015, 16, 592-609. 6.
England, C. G.; Hernandez, R.; Eddine, S. B.; Cai, W.
Molecular Imaging of
Pancreatic Cancer with Antibodies. Mol Pharm 2016, 13, 8-24. 7.
Shi, S.; Chen, F.; Cai, W.
Biomedical applications of functionalized hollow
mesoporous silica nanoparticles: focusing on molecular imaging. Nanomedicine (Lond) 2013, 8, 2027-39. 8.
Hoffman, J. M.; Gambhir, S. S. Molecular imaging: the vision and opportunity for
radiology in the future. Radiology 2007, 244, 39-47. 9.
Miller, J. C.; Thrall, J. H. Clinical molecular imaging. J Am Coll Radiol 2004, 1, 4-
23. 10.
Pichler, B. J.; Wehrl, H. F.; Judenhofer, M. S. Latest advances in molecular imaging
instrumentation. J Nucl Med 2008, 49, 5S-23S. 11.
Mawlawi, O.; Townsend, D. W.
Multimodality imaging: an update on PET/CT
technology. Eur J Nucl Med Mol Imaging 2009, 36, S15-29. 38
ACS Paragon Plus Environment
Page 39 of 48
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
12.
Cassidy, P. J.; Radda, G. K. Molecular imaging perspectives. J R Soc Interface 2005,
2, 133-44. 13.
Ntziachristos, V.; Razansky, D. Optical and opto-acoustic imaging. Recent Results
Cancer Res 2013, 187, 133-50. 14.
Postema, M.; Gilja, O. H.
Contrast-enhanced and targeted ultrasound. World J
Gastroenterol 2011, 17, 28-41. 15.
Ametamey, S. M.; Honer, M.; Schubiger, P. A. Molecular imaging with PET. Chem
Rev 2008, 108, 1501-16. 16.
Serdons, K.; Verbruggen, A.; Bormans, G. M. Developing new molecular imaging
probes for PET. Methods 2009, 48, 104-11. 17.
Basu, S. Personalized versus evidence-based medicine with PET-based imaging. Nat
Rev Clin Oncol 2010, 7, 665-8. 18.
Bussink, J.; Kaanders, J. H.; van der Graaf, W. T.; Oyen, W. J. PET-CT for
radiotherapy treatment planning and response monitoring in solid tumors. Nat Rev Clin Oncol 2011, 8, 233-42. 19.
Gambhir, S. S. Molecular imaging of cancer with positron emission tomography. Nat
Rev Cancer 2002, 2, 683-93. 20.
Grootjans, W.; de Geus-Oei, L. F.; Troost, E. G.; Visser, E. P.; Oyen, W. J.; Bussink,
J. PET in the management of locally advanced and metastatic NSCLC. Nat Rev Clin Oncol 2015, 12, 395-407. 21.
West, C. M.; Jones, T.; Price, P. The potential of positron-emission tomography to
study anticancer-drug resistance. Nat Rev Cancer 2004, 4, 457-69. 22.
Nanni, C.; Fanti, S. Applications of small animal PET. Recent Results Cancer Res
2013, 187, 247-55.
39
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
23.
Page 40 of 48
Schwaiger, M.; Wester, H. J. How many PET tracers do we need? J Nucl Med 2011,
52, 36S-41S. 24.
Zaidi, H.; Vees, H.; Wissmeyer, M. Molecular PET/CT imaging-guided radiation
therapy treatment planning. Acad Radiol 2009, 16, 1108-33. 25.
Niccoli Asabella, A.; Cascini, G. L.; Altini, C.; Paparella, D.; Notaristefano, A.;
Rubini, G. The copper radioisotopes: a systematic review with special interest to
64
Cu.
Biomed Res Int 2014, 2014, 786463. 26.
Hao, G.; Singh, A. N.; Oz, O. K.; Sun, X.
Recent advances in copper
radiopharmaceuticals. Curr Radiopharm 2011, 4, 109-21. 27.
Shokeen, M.; Wadas, T. J. The development of copper radiopharmaceuticals for
imaging and therapy. Med Chem 2011, 7, 413-29. 28.
Cai, W.; Chen, K.; He, L.; Cao, Q.; Koong, A.; Chen, X. Quantitative PET of EGFR
expression in xenograft-bearing mice using
64
Cu-labeled cetuximab, a chimeric anti-EGFR
monoclonal antibody. Eur J Nucl Med Mol Imaging 2007, 34, 850-8. 29.
Cai, W.; Wu, Y.; Chen, K.; Cao, Q.; Tice, D. A.; Chen, X. In vitro and in vivo
characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res 2006, 66, 9673-81. 30.
Hernandez, R.; Czerwinski, A.; Chakravarty, R.; Graves, S. A.; Yang, Y.; England, C.
G.; Nickles, R. J.; Valenzuela, F.; Cai, W. Evaluation of two novel
64
Cu-labeled RGD
peptide radiotracers for enhanced PET imaging of tumor integrin αvβ3. Eur J Nucl Med Mol Imaging 2015, 42, 1859-68. 31.
Luo, H.; England, C. G.; Graves, S. A.; Sun, H.; Liu, G.; Nickles, R. J.; Cai, W. PET
Imaging of VEGFR-2 Expression in Lung Cancer with
64
Cu-Labeled Ramucirumab. J Nucl
Med 2016, 57, 285-90.
40
ACS Paragon Plus Environment
Page 41 of 48
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
32.
Orbay, H.; Zhang, Y.; Valdovinos, H. F.; Song, G.; Hernandez, R.; Theuer, C. P.;
Hacker, T. A.; Nickles, R. J.; Cai, W. Positron emission tomography imaging of CD105 expression in a rat myocardial infarction model with
64
Cu-NOTA-TRC105. Am J Nucl Med
Mol Imaging 2013, 4, 1-9. 33.
Shi, S.; Orbay, H.; Yang, Y.; Graves, S. A.; Nayak, T. R.; Hong, H.; Hernandez, R.;
Luo, H.; Goel, S.; Theuer, C. P.; Nickles, R. J.; Cai, W. PET Imaging of Abdominal Aortic Aneurysm with
64
Cu-Labeled Anti-CD105 Antibody Fab Fragment. J Nucl Med 2015, 56,
927-32. 34.
Willmann, J. K.; Chen, K.; Wang, H.; Paulmurugan, R.; Rollins, M.; Cai, W.; Wang,
D. S.; Chen, I. Y.; Gheysens, O.; Rodriguez-Porcel, M.; Chen, X.; Gambhir, S. S. Monitoring of the biological response to murine hindlimb ischemia with
64
Cu-labeled
vascular endothelial growth factor-121 positron emission tomography. Circulation 2008, 117, 915-22. 35.
Yang, Y.; Hernandez, R.; Rao, J.; Yin, L.; Qu, Y.; Wu, J.; England, C. G.; Graves, S.
A.; Lewis, C. M.; Wang, P.; Meyerand, M. E.; Nickles, R. J.; Bian, X. W.; Cai, W. Targeting CD146 with a
64
Cu-labeled antibody enables in vivo immunoPET imaging of high-grade
gliomas. Proc Natl Acad Sci U S A 2015, 112, E6525-34. 36.
Chakravarty, R.; Goel, S.; Hong, H.; Chen, F.; Valdovinos, H. F.; Hernandez, R.;
Barnhart, T. E.; Cai, W. Hollow mesoporous silica nanoparticles for tumor vasculature targeting and PET image-guided drug delivery. Nanomedicine (Lond) 2015, 10, 1233-46. 37.
Malmberg, C.; Ripa, R. S.; Johnbeck, C. B.; Knigge, U.; Langer, S. W.; Mortensen,
J.; Oturai, P.; Loft, A.; Hag, A. M.; Kjaer, A. 64Cu-DOTATATE for Noninvasive Assessment of Atherosclerosis in Large Arteries and Its Correlation with Risk Factors: Head-to-Head Comparison with 68Ga-DOTATOC in 60 Patients. J Nucl Med 2015, 56, 1895-900.
41
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
38.
Page 42 of 48
Grassi, I.; Nanni, C.; Cicoria, G.; Blasi, C.; Bunkheila, F.; Lopci, E.; Colletti, P. M.;
Rubello, D.; Fanti, S. Usefulness of
64
Cu-ATSM in head and neck cancer: a preliminary
prospective study. Clin Nucl Med 2014, 39, e59-63. 39.
Zornhagen, K. W.; Clausen, M. M.; Hansen, A. E.; Law, I.; McEvoy, F. J.;
Engelholm, S. A.; Kjaer, A.; Kristensen, A. T. Use of Molecular Imaging Markers of Glycolysis, Hypoxia and Proliferation (18F-FDG,
64
Cu-ATSM and
18
F-FLT) in a Dog with
Fibrosarcoma: The Importance of Individualized Treatment Planning and Monitoring. Diagnostics (Basel) 2015, 5, 372-82. 40.
Pfeifer, A.; Knigge, U.; Binderup, T.; Mortensen, J.; Oturai, P.; Loft, A.; Berthelsen,
A. K.; Langer, S. W.; Rasmussen, P.; Elema, D.; von Benzon, E.; Hojgaard, L.; Kjaer, A. 64
Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head
Comparison with 111In-DTPA-Octreotide in 112 Patients. J Nucl Med 2015, 56, 847-54. 41.
Bourgeois, M.; Rajerison, H.; Guerard, F.; Mougin-Degraef, M.; Barbet, J.; Michel,
N.; Cherel, M.; Faivre-Chauvet, A. Contribution of [64Cu]-ATSM PET in molecular imaging of tumour hypoxia compared to classical [18F]-MISO--a selected review. Nucl Med Rev Cent East Eur 2011, 14, 90-5. 42.
Caroli, P.; Nanni, C.; Rubello, D.; Alavi, A.; Fanti, S. Non-FDG PET in the practice
of oncology. Indian J Cancer 2010, 47, 120-5. 43.
Lopci, E.; Grassi, I.; Chiti, A.; Nanni, C.; Cicoria, G.; Toschi, L.; Fonti, C.; Lodi, F.;
Mattioli, S.; Fanti, S. PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. Am J Nucl Med Mol Imaging 2014, 4, 365-84. 44.
Li, F.; Jorgensen, J. T.; Forman, J.; Hansen, A. E.; Kjaer, A.
64
Cu-ATSM Reflects
pO2 Levels in Human Head and Neck Cancer Xenografts but Not in Colorectal Cancer Xenografts: Comparison with 64CuCl2. J Nucl Med 2016, 57, 437-43.
42
ACS Paragon Plus Environment
Page 43 of 48
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
45.
Vavere, A. L.; Lewis, J. S. Cu-ATSM: a radiopharmaceutical for the PET imaging of
hypoxia. Dalton Trans 2007, 43, 4893-902. 46.
Kim, K. I.; Jang, S. J.; Park, J. H.; Lee, Y. J.; Lee, T. S.; Woo, K. S.; Park, H.; Choe,
J. G.; An, G. I.; Kang, J. H. Detection of increased 64Cu uptake by human copper transporter 1 gene overexpression using PET with
64
CuCl2 in human breast cancer xenograft model. J
Nucl Med 2014, 55, 1692-8. 47.
Peng, F.; Lu, X.; Janisse, J.; Muzik, O.; Shields, A. F. PET of human prostate cancer
xenografts in mice with increased uptake of 64CuCl2. J Nucl Med 2006, 47, 1649-52. 48.
Qin, C.; Liu, H.; Chen, K.; Hu, X.; Ma, X.; Lan, X.; Zhang, Y.; Cheng, Z.
Theranostics of malignant melanoma with 64CuCl2. J Nucl Med 2014, 55, 812-7. 49.
McCarthy, D. W.; Shefer, R. E.; Klinkowstein, R. E.; Bass, L. A.; Margeneau, W. H.;
Cutler, C. S.; Anderson, C. J.; Welch, M. J. Efficient production of high specific activity 64
Cu using a biomedical cyclotron. Nucl Med Biol 1997, 24, 35-43.
50.
Bokhari, T. H.; Mushtaq, A.; Khan, I. U. Production of low and high specific activity
64
Cu in a reactor. J Radioanal Nucl Chem 2010, 284, 265-71.
51.
Vimalnath, K. V.; Rajeswari, A.; Chirayil, V.; Sharad, P. L.; Jagadeesan, K. C.; Joshi,
P. V.; Venkatesh, M. Studies on preparation of 64Cu using (n,γ) route of reactor production using medium flux research reactor in India. J Radioanal Nucl Chem 2011, 290, 221-5. 52.
Chakravarty, R.; Chakraborty, S.; Vimalnath, K. V.; Shetty, P.; Sarma, H. D.; Hassan,
P. A.; Dash, A. 64CuCl2 produced by direct neutron activation route as a cost-effective probe for cancer imaging: the journey has begun. RSC Adv 2015, 5, 91723-33. 53.
Lin, T. K.; Yeh, S. J. Enrichment of Copper-64 by the Szilard Chalmers Process. J
Nucl Sci Technol 1966, 3, 289-93. 54.
Radioisotope Production and Quality Control, International Atomic Energy Agency
(IAEA) - Technical Reports Series No. 128 (1971). 43
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
55.
Page 44 of 48
Manrique-Arias, J. C.; Avila-Rodriguez, M. A. A simple and efficient method of
nickel electrodeposition for the cyclotron production of 64Cu. Appl Radiat Isot 2014, 89, 3741. 56.
Cyclotron produced radionuclides: emerging positron emitters for medical
applications : 64Cu and 124I, International Atomic Energy Agency (IAEA) Radioisotopes and Radiopharmaceuticals Reports No. 1 (2016). 57.
Avila-Rodriguez, M. A.; Nye, J. A.; Nickles, R. J. Simultaneous production of high
specific activity 64Cu and 61Co with 11.4 MeV protons on enriched 64Ni nuclei. Appl Radiat Isot 2007, 65, 1115-20. 58.
Ometáková, J.; Rajec, P.; Csiba, V.; Leporis, M.; Štefečka, M.; Vlk, P.; Galamboš,
M.; Rosskopfová, O. Automated production of
64
Cu prepared by 18 MeV cyclotron. J
Radioanal Nucl Chem 2012, 293, 217-22. 59.
Elomaa, V. V.; Jurttila, J.; Rajander, J.; Solin, O. Automation of 64Cu production at
Turku PET Centre. Appl Radiat Isot 2014, 89, 74-8. 60.
Matarrese, M.; Bedeschi, P.; Scardaoni, R.; Sudati, F.; Savi, A.; Pepe, A.; Masiello,
V.; Todde, S.; Gianolli, L.; Messa, C.; Fazio, F. Automated production of copper radioisotopes and preparation of high specific activity [64Cu]Cu-ATSM for PET studies. Appl Radiat Isot 2010, 68, 5-13. 61.
Shokeen, M.; Anderson, C. J. Molecular imaging of cancer with copper-64
radiopharmaceuticals and positron emission tomography (PET). Acc Chem Res 2009, 42, 832-41. 62.
International Atomic Energy Agency. Operation Research Reactors in the World
[database].
Available
at:
www.naweb.iaea.org/napc/physics/research_reactors/database/RR%20Data%20Base/datase ts/foreword_home.html. 44
ACS Paragon Plus Environment
Page 45 of 48
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
63.
Verwilst, P.; Sunwoo, K.; Kim, J. S. The role of copper ions in pathophysiology and
fluorescent sensors for the detection thereof. Chem Commun (Camb) 2015, 51, 5556-71. 64.
Llanos, R. M.; Mercer, J. F. The molecular basis of copper homeostasis copper-
related disorders. DNA Cell Biol 2002, 21, 259-70. 65.
Mercer, J. F.; Llanos, R. M. Molecular and cellular aspects of copper transport in
developing mammals. J Nutr 2003, 133, 1481S-4S. 66.
Camakaris, J.; Voskoboinik, I.; Mercer, J. F.
Molecular mechanisms of copper
homeostasis. Biochem Biophys Res Commun 1999, 261, 225-32. 67.
Denoyer, D.; Masaldan, S.; La Fontaine, S.; Cater, M. A. Targeting copper in cancer
therapy: 'Copper That Cancer'. Metallomics 2015, 7, 1459-76. 68.
Wang, F.; Jiao, P.; Qi, M.; Frezza, M.; Dou, Q. P.; Yan, B. Turning tumor-promoting
copper into an anti-cancer weapon via high-throughput chemistry. Curr Med Chem 2010, 17, 2685-98. 69.
Jackson, G. E.; Byrne, M. J. Metal ion speciation in blood plasma: gallium-67-citrate
and MRI contrast agents. J Nucl Med 1996, 37, 379-86. 70.
Timerbaev, A. R.
Determination of metal species in biological samples: From
speciation analysis to metallomics. J Anal Chem 2012, 67, 179-85. 71.
Peng, F.; Liu, J.; Wu, J. S.; Lu, X.; Muzik, O. Mouse extrahepatic hepatoma detected
on MicroPET using copper (II)-64 chloride uptake mediated by endogenous mouse copper transporter 1. Mol Imaging Biol 2005, 7, 325-9. 72.
Cai, H.; Wu, J. S.; Muzik, O.; Hsieh, J. T.; Lee, R. J.; Peng, F. Reduced 64Cu uptake
and tumor growth inhibition by knockdown of human copper transporter 1 in xenograft mouse model of prostate cancer. J Nucl Med 2014, 55, 622-8.
45
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
73.
Jorgensen, J. T.; Persson, M.; Madsen, J.; Kjaer, A. High tumor uptake of
Page 46 of 48
64
Cu:
implications for molecular imaging of tumor characteristics with copper-based PET tracers. Nucl Med Biol 2013, 40, 345-50. 74.
Ferrari, C.; Asabella, A. N.; Villano, C.; Giacobbi, B.; Coccetti, D.; Panichelli, P.;
Rubini, G. Copper-64 Dichloride as Theranostic Agent for Glioblastoma Multiforme: A Preclinical Study. Biomed Res Int 2015, 2015, 129764. 75.
Bal, W.; Sokolowska, M.; Kurowska, E.; Faller, P. Binding of transition metal ions to
albumin: sites, affinities and rates. Biochim Biophys Acta 2013, 1830, 5444-55. 76.
Sarkar, B. Metal protein interactions. Prog Food Nutr Sci 1987, 11, 363-400.
77.
Duff, M. R., Jr.; Kumar, C. V. The metallomics approach: use of Fe(II) and Cu(II)
footprinting to examine metal binding sites on serum albumins. Metallomics 2009, 1, 518-23. 78.
Hassan, P. A.; Rana, S.; Verma, G. Making sense of Brownian motion: colloid
characterization by dynamic light scattering. Langmuir 2015, 31, 3-12. 79.
Duatti, A. Molecular imaging with endogenous and exogenous ligands: the instance
of antibodies, peptides, iodide and cupric ions. Nucl Med Biol 2015, 42, 215-8. 80.
Capasso, E.; Durzu, S.; Piras, S.; Zandieh, S.; Knoll, P.; Haug, A.; Hacker, M.;
Meleddu, C.; Mirzaei, S. Role of
64
CuCl2 PET/CT in staging of prostate cancer. Ann Nucl
Med 2015, 29, 482-8. 81.
Panichelli, P.; Villano, C.; Cistaro, A.; Bruno, A.; Barbato, F.; Piccardo, A.; Duatti,
A.
Imaging of Brain Tumors with Copper-64 Chloride: Early Experience and Results.
Cancer Biother Radiopharm 2016, 31, 159-67. 82.
Wu, J.; Wang, L.; He, J.; Zhu, C. In vitro cytotoxicity of Cu2+, Zn2+, Ag+ and their
mixtures on primary human endometrial epithelial cells. Contraception 2012, 85, 509-18. 83.
Cao, B.; Zheng, Y.; Xi, T.; Zhang, C.; Song, W.; Burugapalli, K.; Yang, H.; Ma, Y.
Concentration-dependent cytotoxicity of copper ions on mouse fibroblasts in vitro: effects of 46
ACS Paragon Plus Environment
Page 47 of 48
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
copper ion release from TCu380A vs TCu220C intra-uterine devices. Biomed Microdevices 2012, 14, 709-20. 84.
Arnal, N.; de Alaniz, M. J.; Marra, C. A. Cytotoxic effects of copper overload on
human-derived lung and liver cells in culture. Biochim Biophys Acta 2012, 1820, 931-9. 85.
Grillo, C. A.; Reigosa, M. A.; de Mele, M. A. Does over-exposure to copper ions
released from metallic copper induce cytotoxic and genotoxic effects on mammalian cells? Contraception 2010, 81, 343-9. 86.
Grillo, C. A.; Reigosa, M. A.; Lorenzo de Mele, M. F. Effects of copper ions released
from metallic copper on CHO-K1 cells. Mutat Res 2009, 672, 45-50. 87.
Uriu-Adams, J. Y.; Keen, C. L. Copper, oxidative stress, and human health. Mol
Aspects Med 2005, 26, 268-98. 88.
Valko, M.; Rhodes, C. J.; Moncol, J.; Izakovic, M.; Mazur, M. Free radicals, metals
and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006, 160, 1-40. 89.
Lutsenko, S. Human copper homeostasis: a network of interconnected pathways.
Curr Opin Chem Biol 2010, 14, 211-7. 90.
Wang, H.; Chen, X. Visualization of copper metabolism by
64
CuCl2-PET. Mol
Imaging Biol 2012, 14, 14-6. 91.
Bush, J. A.; Mahoney, J. P.; Markowitz, H.; Gubler, C. J.; Cartwright, G. E.;
Wintrobe, M. M. Studies on copper metabolism. XIV. Radioactive copper studies in normal subjects and in patients with hepatolenticular degeneration. J Clin Invest 1955, 34, 1766-78. 92.
Walshe, J. M.; Potter, G. The pattern of the whole body distribution of radioactive
copper (67Cu, 64Cu) in Wilson's Disease and various control groups. Q J Med 1977, 46, 44562.
47
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
64
Page 48 of 48
Cu2+ Ions as PET Probe: An Emerging Paradigm in Molecular Imaging of Cancer Rubel Chakravarty,* Sudipta Chakraborty and Ashutosh Dash
Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400 085, India
Graphical Abstract
PET Imaging 64Cu2+
64Cu
ions as probe
t½ = 12.9 h
Clinical Preclinical 64
Cu in the form of Cu2+ ions can directly be used as a radiotracer for PET imaging of various
types of cancers in preclinical and clinical settings.
48
ACS Paragon Plus Environment